Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tazarotene + betamethasone dipropionate
- Development stage
- Unknown
- Lead developer
- Chongqing Huapont Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Lefusong is a topical combination therapy developed by Chongqing Huabang Pharmaceutical for the treatment of chronic plaque psoriasis. It contains tazarotene, a third-generation retinoid, and betamethasone dipropionate, a potent synthetic corticosteroid. Tazarotene acts as a selective agonist for retinoic acid receptors (RARs), specifically RAR-beta and RAR-gamma, which helps normalize keratinocyte differentiation and reduce epidermal hyperplasia. Betamethasone dipropionate acts as a glucocorticoid receptor agonist, providing anti-inflammatory, antipruritic, and immunosuppressive effects by inhibiting the release of inflammatory mediators. The combination is designed to enhance efficacy while potentially mitigating the irritation often associated with retinoid monotherapy.
- Brand names
- Lefusong
- Other names
- Tazarotene and Betamethasone Dipropionate Cream
02
Targets
GR (Glucocorticoid receptor)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on tazarotene + betamethasone dipropionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tazarotene + betamethasone dipropionate.